| MARK3 | Clinical trial target | Cdc25C-associated protein kinase 1;cTAK1;C-TAK1;MAP/microtubule affinity-regulating kinase 3;Protein kinase STK10);Ser/Thr protein kinase PAR-1;Serine/threonine-protein kinase p78 | Renal cell carcinoma;Leukemia | 7-hydroxystaurosporine;CBP-501 | 7-hydroxystaurosporine;CBP-501;compound 17d | |